Swiss National Bank grew its position in Flexion Therapeutics Inc (NASDAQ:FLXN) by 8.5% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 59,911 shares of the specialty pharmaceutical company’s stock after purchasing an additional 4,700 shares during the period. Swiss National Bank owned about 0.16% of Flexion Therapeutics worth $737,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of FLXN. BNP Paribas Arbitrage SA increased its position in Flexion Therapeutics by 53,692.3% in the 1st quarter. BNP Paribas Arbitrage SA now owns 6,993 shares of the specialty pharmaceutical company’s stock worth $87,000 after purchasing an additional 6,980 shares during the last quarter. SG Americas Securities LLC acquired a new position in Flexion Therapeutics in the 1st quarter worth about $338,000. Raymond James Financial Services Advisors Inc. increased its position in Flexion Therapeutics by 46.2% in the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 106,164 shares of the specialty pharmaceutical company’s stock worth $1,325,000 after purchasing an additional 33,569 shares during the last quarter. Spark Investment Management LLC acquired a new position in Flexion Therapeutics in the 1st quarter worth about $1,457,000. Finally, Wasatch Advisors Inc. increased its position in Flexion Therapeutics by 7.8% in the 1st quarter. Wasatch Advisors Inc. now owns 1,016,137 shares of the specialty pharmaceutical company’s stock worth $12,681,000 after purchasing an additional 73,751 shares during the last quarter. 84.87% of the stock is currently owned by institutional investors.

In related news, insider Michael D. Clayman acquired 2,317 shares of the stock in a transaction dated Thursday, August 8th. The shares were acquired at an average price of $10.85 per share, with a total value of $25,139.45. Following the acquisition, the insider now owns 72,249 shares in the company, valued at approximately $783,901.65. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 16.01% of the company’s stock.

Several research analysts have weighed in on the company. BidaskClub raised Flexion Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, September 4th. Northland Securities set a $20.00 target price on Flexion Therapeutics and gave the stock a “buy” rating in a research report on Tuesday. Zacks Investment Research raised Flexion Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a research report on Saturday, August 10th. Finally, ValuEngine raised Flexion Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday. Ten equities research analysts have rated the stock with a buy rating, Flexion Therapeutics has an average rating of “Buy” and an average target price of $23.57.

Shares of NASDAQ FLXN traded down $0.23 during mid-day trading on Friday, reaching $13.90. 71,040 shares of the company traded hands, compared to its average volume of 520,452. The company has a debt-to-equity ratio of 3.95, a quick ratio of 7.33 and a current ratio of 7.80. The stock has a market cap of $543.02 million, a PE ratio of -3.10 and a beta of 1.23. The company’s fifty day moving average is $11.29 and its two-hundred day moving average is $11.69. Flexion Therapeutics Inc has a fifty-two week low of $8.76 and a fifty-two week high of $21.77.

Flexion Therapeutics (NASDAQ:FLXN) last issued its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported ($0.96) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.06) by $0.10. The business had revenue of $16.95 million for the quarter, compared to analyst estimates of $14.03 million. Flexion Therapeutics had a negative return on equity of 175.29% and a negative net margin of 368.31%. Research analysts forecast that Flexion Therapeutics Inc will post -4.02 earnings per share for the current year.

About Flexion Therapeutics

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States.

Recommended Story: What is total return in investing?

Institutional Ownership by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.